Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,969.90 | 10.20 | 0.13% |
| CAC 40 | 7,335.40 | 62.28 | 0.86% |
| DAX 40 | 21,253.70 | 298.87 | 1.43% |
| Dow JONES (US) | 40,368.96 | 155.83 | -0.38% |
| FTSE 100 | 8,249.12 | 114.78 | 1.41% |
| HKSE | 21,466.27 | 48.87 | 0.23% |
| NASDAQ | 16,823.17 | 8.32 | -0.05% |
| Nikkei 225 | 34,267.54 | 285.18 | 0.84% |
| NZX 50 Index | 12,011.34 | 96.20 | -0.79% |
| S&P 500 | 5,396.63 | 9.34 | -0.17% |
| S&P/ASX 200 | 7,761.70 | 13.10 | 0.17% |
| SSE Composite Index | 3,267.66 | 4.85 | 0.15% |